Drugs / PF-07263689
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05061537 | Oct 2021 → Oct 2022 | colorectal cancer, head and neck cancer, hepatocellular carcinoma, melanoma +6 | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07263689 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05061537 ↗ |
| Route | Intravenous | “PF-07263689 intravenous (IV)” NCT05061537 ↗ |